Compounders Research Compare

Adial Pharmaceuticals, Inc.(ADIL)

Biotechnology · Glen Allen, VA

$4.35+0.23 (+5.58%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Glen Allen, VA

5 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cary John Claiborne

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T13:25:16.195Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:16.195Z.

Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 11,422,621
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 28,712,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ADIL EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ADIL Competitors' EV/EBITDA Ratio

Adial Pharmaceuticals, Inc.

Current

Market Cap

$11.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Biofrontera Inc.

Market Cap

$11.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kiora Pharmaceuticals, Inc.

Market Cap

$11.21M

EV/EBITDA Ratio

N/A

TTM Avg

12.81x

3Y Avg

12.81x

5Y Avg

12.81x

Bullfrog AI Holdings, Inc. Common Stock

Market Cap

$11.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRIDEX Corporation

Market Cap

$11.94M

EV/EBITDA Ratio

N/A

TTM Avg

133.45x

3Y Avg

63.52x

5Y Avg

51.85x

CytoMed Therapeutics Limited

Market Cap

$11.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioVie Inc.

Market Cap

$10.86M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lifeward Ltd.

Market Cap

$10.75M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cerenome, Inc.

Market Cap

$10.74M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cytosorbents Corporation

Market Cap

$12.46M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Adial Pharmaceuticals, Inc. (ADIL)	$11.42M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.41M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.21M	N/A	12.81x	12.81x	12.81x
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.01M	N/A	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$11.94M	N/A	133.45x	63.52x	51.85x
CytoMed Therapeutics Limited (GDTC)vs ›	$11.95M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$10.86M	N/A	N/A	N/A	N/A
Lifeward Ltd. (LFWD)vs ›	$10.75M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$10.74M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$12.46M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics